Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Stage IIIA Endometrial Carcinoma
Endometrial Adenosquamous Cell Carcinoma
Endometrial Papillary Serous Carcinoma
Endometrial Adenocarcinoma
Stage IIIB Endometrial Carcinoma
Stage IIIC Endometrial Carcinoma
Endometrial Clear Cell Carcinoma
Recurrent Endometrial Carcinoma
Stage IVA Endometrial Carcinoma
Stage IVB Endometrial Carcinoma

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2003-11-06

Last Posted Date: 2015-02-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00072176

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

CCI-779 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Metastatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-07-15

Last Posted Date: 2012-08-09

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 15

Registration Number: NCT00003712

Locations: 🇺🇸
San Antonio Cancer Institute, San Antonio, Texas, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: temsirolimus
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00028028

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00016328

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Phase 1

Completed

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00045370

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

CCI-779 in Treating Patients With Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2018-06-26

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 49

Registration Number: NCT00022724

Locations: 🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

and more 7 locations

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma

Interventions: Drug: temsirolimus

First Posted Date: 2003-01-27

Last Posted Date: 2014-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00033267

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

CCI-779 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-01-27

Last Posted Date: 2015-06-08

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT00022464

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
LaGrange Memorial Hospital, LaGrange, Illinois, United States
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy